Evidence map›Paper›PMID 34942174›Full record

ArticleChest2022

COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition.

Bruno Guedes Baldi, Elzbieta Radzikowska, Vincent Cottin, Daniel F Dilling, Ali Ataya, Carlos Roberto Ribeiro Carvalho, Sergio Harari, Matthew Koslow, Jan C Grutters, Yoshikazu Inoue and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Guideline
  2. Trial
  3. Article
  4. Article
  5. COVID-19 and pulmonary alveolar proteinosis: an unusual combination.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 7 countries.

Bruno Guedes BaldiDivisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Electronic address: bruno.baldi@hc.fm.usp.br.
Elzbieta RadzikowskaNational Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
Vincent CottinNational Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, INRAE, Lyon, France.
Daniel F DillingDivision of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL.
Ali AtayaDivision of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL.
Carlos Roberto Ribeiro CarvalhoDivisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Sergio HarariDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Department of Medicine, Ospedale San Giuseppe MultiMedica IRCCS, Milan, Italy.
Matthew KoslowILD Program, Department of Medicine, National Jewish Health, Denver, CO.
Jan C GruttersILD Center of Excellence, St. Antonius Hospital Nieuwegein, University Medical Center Utrecht, Utrecht, The Netherlands.
Yoshikazu InoueClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Nishant GuptaDivision of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, OH.
Simon R JohnsonTranslational Medical Sciences, NIHR Biomedical Research Centre and Biodiscovery Institute, University of Nottingham, Nottingham, England; National Centre for Lymphangioleiomyomatosis, Nottingham University Hospitals NHS Trust, Nottingham, England.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHôpital Louis Pradel · FRLoyola University Chicago · USNational Jewish Health · USNational Kinki Chuo Hospital for Chest Disease · JPNottingham University Hospitals NHS Trust · GBOspedale San Giuseppe · ITUniversity Medical Center Utrecht · NLUniversity of Cincinnati · USUniversity of Florida · US

Funding

Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCCU01HL131755 · NHLBI · UNIVERSITY OF CINCINNATI · PI MCCORMACK, FRANCIS XAVIER · 2016 to 2021
$3.6M
Resveratrol and Sirolimus in LAM Trial (RESULT)R34HL138235 · NHLBI · UNIVERSITY OF CINCINNATI · PI GUPTA, NISHANT · 2017 to 2019
$712k
Medical Research CouncilNHLBI NIH HHS R34 HL138235NHLBI NIH HHS U01 HL131755
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Lung NeoplasmsLymphangioleiomyomatosisHumansSirolimusTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsSirolimusTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Identifiers

PMID34942174
PMCPMC8687712
OpenAlexW4200076807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.